Follow

Statement re Media Article

08 February 2021 - 07:00
RNS Number : 2371O
Abingdon Health PLC
08 February 2021
 

 

Statement re Media Article

 

York, U.K. 8 February 2021:  Abingdon Health plc (AIM: ABDX) ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, notes the article published in the Daily Mail on 6 February 2021 and refers investors to the RNS announcements made on 29 December 2020, 26 January 2021 and 27 January 2021 which accurately reflect the Company's position and current performance.

 

 

Enquiries:

Abingdon Health plc



Chris Yates

Chief Executive Officer

Via Consilium

Melanie Ross

Chief Financial Officer


Chris Hand

Non-Executive Chairman





N+1 Singer

Sole Broker and Nominated Adviser

Shaun Dobson, Peter Steel,


Tel: +44 (0) 20 7496 3000

Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)





Consilium

Financial PR

Tel: +44 (0) 7720 088 468

Matthew Neal

[email protected]

Mary-Jane Elliott             



Lindsey Neville



 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCFDLLBFLLFBBQ
Provided by: RNS
London AIM (United Kingdom)
Abingdon Health plc
Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More